SNOA has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
SNOA has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
YoY EPS Growth is the percentage change of Earnings per Share (Diluted) over the past twelve months. Sonoma Pharmaceuticals's YoY EPS Growth for the quarter that ended in Dec. 2023 was 87.10%.
Sonoma Pharmaceuticals's Earnings per Share (Diluted) for the three months ended in Dec. 2023 was $-0.08.
The historical data trend for Sonoma Pharmaceuticals's YoY EPS Growth can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sonoma Pharmaceuticals Annual Data | |||||||||||||||||||||
Trend | Mar14 | Mar15 | Mar16 | Mar17 | Mar18 | Mar19 | Mar20 | Mar21 | Mar22 | Mar23 | |||||||||||
YoY EPS Growth | Get a 7-Day Free Trial | 55.18 | 82.46 | 12.05 | 2.54 | 20.83 |
Sonoma Pharmaceuticals Quarterly Data | ||||||||||||||||||||
Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | |
YoY EPS Growth | Get a 7-Day Free Trial | -100.00 | 73.83 | - | 12.12 | 87.10 |
YoY EPS Growth is the percentage change of Earnings per Share (Diluted) over the past twelve months.
Sonoma Pharmaceuticals's YoY EPS Growth for the fiscal year that ended in Mar. 2023 is calculated as:
YoY EPS Growth (A: Mar. 2023 ) | |||||
= | (Earnings per Share (Diluted) (A: Mar. 2023 ) | - | Earnings per Share (Diluted) (A: Mar. 2022 )) | / | | Earnings per Share (Diluted) (A: Mar. 2022 ) | |
= | (-1.52 | - | -1.92) | / | | -1.92 | |
= | 20.83 % |
Sonoma Pharmaceuticals's YoY EPS Growth for the quarter that ended in Dec. 2023 is calculated as:
YoY EPS Growth (Q: Dec. 2023 ) | |||||
= | (Earnings per Share (Diluted) (Q: Dec. 2023 ) | - | Earnings per Share (Diluted) (Q: Dec. 2022 )) | / | | Earnings per Share (Diluted) (Q: Dec. 2022 )) | |
= | (-0.08 | - | -0.62) | / | | -0.62 | |
= | 87.10 % |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Thank you for viewing the detailed overview of Sonoma Pharmaceuticals's YoY EPS Growth provided by GuruFocus.com. Please click on the following links to see related term pages.
Chad Norman White | officer: Interim CFO | 645 MOLLY LANE, SUITE 150, WOODSTOCK GA 30189 |
Jerome J Dvonch | officer: Chief Financial Officer | 12701 COMMONWEALTH DRIVE, SUITE 9, FORT MYERS FL 33913 |
Robert Grant Edwards | officer: Chief Financial Officer | 1129 N. MCDOWELL BLVD., PETALUMA CA 94954 |
Poggetto John Dal | officer: Chief Financial Officer | 1129 N. MCDOWELL BLVD, PETALUMA CA 94954 |
Amy Moss Trombly | officer: Interim CEO | 1314 MAIN STREET, SUITE 102, LOUSIVILLE CO 80027 |
Frederick J Sandford | director, officer: CEO and Interim CFO | C/O SONOMA PHARMACEUTICALS, INC., 1129 N. MCDOWELL BLVD., PETALUMA CA 94954 |
Philippe Weigerstorfer | director | 1129 N. MCDOWELL BLVD., PETALUMA CA 94954 |
Robert E Miller | officer: Chief Financial Officer | 1129 N. MCDOWELL BLVD., PETALUMA CA 94954 |
James J Schutz | director, officer: Chief Operating Officer | 1129 N. MCDOWELL BLVD., PETALUMA CA 94954 |
Marc Umscheid | officer: Chief Strategy/Mkt Officer | OCULUS INNOVATIVE SCIENCES, INC., 1129 N. MCDOWELL BLVD., PETALUMA CA 94954 |
Robert Allen Northey | officer: Exec. VP of Res & Devlpment | C/O OCULUS INNOVATIVE SCIENCES, INC., 1129 N. MCDOWELL BLVD., PETALUMA CA 94954 |
Sharon Surrey Barbari | director | 280 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080 |
Russell Joseph Harrison | director | OCULUS INNOVATIVE SCIENCES, INC., 1129 NORTH MCDOWELL BLVD., PETALUMA CA 94954 |
John Mclaughlin | director | OCULUS INNOVATIVE SCIENCES, INC., 1129 N. MCDOWELL BLVD., PETALUMA CA 94954 |
Sameer Harish | other: Officer of Subsidiary (1) | RUTHIGEN, INC., 1129 N. MCDOWELL BLVD, PETALUMA CA 94954 |
From GuruFocus
By GF Value GF Value • 04-01-2021
By ACCESSWIRE ACCESSWIRE • 01-04-2023
By ACCESSWIRE ACCESSWIRE • 06-09-2023
By ACCESSWIRE • 10-26-2023
By ACCESSWIRE ACCESSWIRE • 03-29-2023
By ACCESSWIRE • 08-11-2023
By ACCESSWIRE ACCESSWIRE • 01-31-2023
By Business Wire Business Wire • 08-19-2021
By Business Wire Business Wire • 11-09-2021
By ACCESSWIRE • 08-15-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.